Mei Sheng Duh

11.8k total citations · 1 hit paper
429 papers, 8.5k citations indexed

About

Mei Sheng Duh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hematology. According to data from OpenAlex, Mei Sheng Duh has authored 429 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Pulmonary and Respiratory Medicine, 89 papers in Oncology and 86 papers in Hematology. Recurrent topics in Mei Sheng Duh's work include Asthma and respiratory diseases (31 papers), Multiple Myeloma Research and Treatments (29 papers) and Renal cell carcinoma treatment (28 papers). Mei Sheng Duh is often cited by papers focused on Asthma and respiratory diseases (31 papers), Multiple Myeloma Research and Treatments (29 papers) and Renal cell carcinoma treatment (28 papers). Mei Sheng Duh collaborates with scholars based in United States, Canada and United Kingdom. Mei Sheng Duh's co-authors include Patrick Lefèbvre, François Laliberté, Marie‐Hélène Lafeuille, Jennifer Weiner, Francis Vekeman, Marianne Cunnington, Ronald G. Pearl, Edward Abraham, Marc J. Shapiro and Neil R. MacIntyre and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Mei Sheng Duh

404 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The CRIT Study: Anemia and blood transfusion in the critically ill—Current clinical practice in the United States*

2004 941 citations Mei Sheng Duh et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mei Sheng Duh United States	44	2.1k	1.2k	1.2k	1.2k	1.1k	429	8.5k
Jodi B Segal United States	59	767 0.4×	586 0.5×	596 0.5×	281 0.2×	2.0k 1.8×	247	12.4k
Lodovico Balducci United States	59	2.9k 1.4×	5.8k 4.8×	978 0.8×	345 0.3×	1.2k 1.0×	283	11.8k
David A. Roth United States	47	2.9k 1.4×	1.1k 0.9×	810 0.7×	432 0.4×	1.4k 1.3×	212	20.6k
David Goldsmith United Kingdom	62	2.0k 1.0×	657 0.5×	818 0.7×	486 0.4×	808 0.7×	359	11.2k
Qilong Yi Canada	54	1.5k 0.7×	831 0.7×	265 0.2×	247 0.2×	1.2k 1.1×	204	10.7k
Jérôme Rossert France	44	1.5k 0.7×	573 0.5×	654 0.5×	165 0.1×	1.8k 1.7×	107	11.4k
Deborah Symmons United Kingdom	87	1.3k 0.6×	1.3k 1.0×	474 0.4×	1.1k 0.9×	5.1k 4.6×	396	27.2k
Bernd Holleczek Germany	48	1.2k 0.6×	2.6k 2.2×	802 0.7×	391 0.3×	293 0.3×	237	8.0k
Gabriel Baron France	43	779 0.4×	442 0.4×	390 0.3×	343 0.3×	604 0.5×	117	8.4k
Susan R. Kahn Canada	70	2.1k 1.0×	521 0.4×	890 0.7×	326 0.3×	4.2k 3.8×	330	25.8k

Countries citing papers authored by Mei Sheng Duh

Since Specialization

Citations

This map shows the geographic impact of Mei Sheng Duh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei Sheng Duh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei Sheng Duh more than expected).

Fields of papers citing papers by Mei Sheng Duh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mei Sheng Duh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei Sheng Duh. The network helps show where Mei Sheng Duh may publish in the future.

Co-authorship network of co-authors of Mei Sheng Duh

This figure shows the co-authorship network connecting the top 25 collaborators of Mei Sheng Duh. A scholar is included among the top collaborators of Mei Sheng Duh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei Sheng Duh. Mei Sheng Duh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Soumerai, Jacob D., Lynn Huynh, Yichuan Grace Hsieh, et al.. (2024). IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence. Blood Advances. 8(16). 4239–4249. 6 indexed citations

Bogart, Michael, Guillaume Germain, François Laliberté, Dominique Lejeune, & Mei Sheng Duh. (2023). Real-World Treatment Patterns and Switching Following Moderate/Severe Chronic Obstructive Pulmonary Disease Exacerbation in Patients with Commercial or Medicare Insurance in the United States. International Journal of COPD. Volume 18. 1575–1586. 6 indexed citations

Lin, Kevin, Lynn Huynh, Mohammed Z.H. Farooqui, et al.. (2023). Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.. Journal of Clinical Oncology. 41(16_suppl). e19510–e19510. 1 indexed citations

DerSarkissian, Maral, et al.. (2023). Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL). Expert Review of Pharmacoeconomics & Outcomes Research. 23(6). 651–658.

Laliberté, François, et al.. (2022). Impact of adherence to treatment with inhaled corticosteroids/long-acting β-agonists on asthma outcomes in the United States. Therapeutic Advances in Respiratory Disease. 16. 2673696325–2673696325. 9 indexed citations

Priest, Julie, Rachel H. Bhak, Maral DerSarkissian, et al.. (2021). Retrospective analysis of adherence to HIV treatment and healthcare utilization in a commercially insured population. Journal of Medical Economics. 24(1). 1204–1211. 6 indexed citations

Moretz, Chad, Guillaume Germain, François Laliberté, et al.. (2021). Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease. Pulmonary Therapy. 7(1). 203–219. 4 indexed citations

Metz, David C., Eric Liu, Vijay N. Joish, et al.. (2020). <p>Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome</p>. Cancer Management and Research. Volume 12. 9713–9719. 3 indexed citations

Ryan, Kellie, et al.. (2020). Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer. PLoS ONE. 15(3). e0230444–e0230444. 5 indexed citations

10.

Ghaswalla, Parinaz, Philippe Thompson‐Leduc, Wendy Y. Cheng, et al.. (2020). 24. Economic Burden of Herpes Zoster Among Individuals with Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study. Open Forum Infectious Diseases. 7(Supplement_1). S35–S36. 1 indexed citations

11.

Wells, J. Connor, Shaan Dudani, Gan Chen, et al.. (2020). Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma. European Urology Open Science. 19. e1105–e1106. 1 indexed citations

12.

Ramasamy, Abhilasha, François Laliberté, Dominique Lejeune, et al.. (2019). Direct, Absenteeism, and Disability Cost Burden of Obesity Among Privately Insured Employees. Journal of Occupational and Environmental Medicine. 62(2). 98–107. 2 indexed citations

13.

Zonnenberg, Bernard A., Maureen P. Neary, Mei Sheng Duh, et al.. (2018). Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus. PLoS ONE. 13(11). e0204646–e0204646. 11 indexed citations

14.

Vekeman, Francis, Jalal A. Aram, Raluca Ionescu‐Ittu, et al.. (2018). Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication. BMC Infectious Diseases. 18(1). 438–438. 10 indexed citations

15.

Mapel, Douglas W., François Laliberté, Melissa Roberts, et al.. (2017). A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. International Journal of COPD. Volume 12. 1825–1836. 14 indexed citations

16.

Kruse, Gregory, Bruce Wong, Mei Sheng Duh, et al.. (2015). Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment. PharmacoEconomics. 33(10). 1049–1067. 2 indexed citations

17.

Labiner, David M., Pierre Emmanuel Paradis, R Manjunath, et al.. (2010). Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology. 74(20). 1566–1574. 53 indexed citations

18.

Faught, Edward, Mei Sheng Duh, Jennifer Weiner, A. Guérin, & Marianne Cunnington. (2008). Nonadherence to antiepileptic drugs and increased mortality. Neurology. 71(20). 1572–1578. 299 indexed citations

19.

Faught, Edward, Jennifer Weiner, Annie Guérin, Marianne Cunnington, & Mei Sheng Duh. (2008). Impact of nonadherence to antiepileptic drugs on health care utilization and costs: Findings from the RANSOM study. Epilepsia. 50(3). 501–509. 182 indexed citations

20.

Duh, Mei Sheng, Samir H. Mody, Patrick Lefèbvre, et al.. (2008). Anaemia and the Risk of Injurious Falls in a Community-Dwelling Elderly Population. Drugs & Aging. 25(4). 325–334. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact